Amgen - 52 Week High | 52 WeekHighLow

Facebook (FB)

JP Morgan (JPM)

AutoZone (AZO)

Yahoo (YHOO)

Apple (AAPL)

Medtronic Reports Fourth Quarter Earnings

Cracker Barrel Reports Earnings, Increases Guidance

Best ETFs For Facebook Exposure

Is Yum! Brands Closing in to Support?

Intuitive Surgical Bullish Signs

Amgen - 52 Week High

Published on Wednesday, 18 January 2012 11:34 Written by Danny Miller

amgn New York, January 18th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) booked a new 52 week high today by trading above $68.47, traders are definitely monitoring Amgen's price action to see if this move attracts further buying into the stock.

Amgen Inc. (NASDAQ:AMGN) develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The company concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.

Amgen is currently trading 1% versus its previous trading session close, and it has calculated support and resistance at $56.00 and $67.78 respectively. Clearly with this action this range has been penetrated, and traders will be reviewing price action to establish a new tradable range

The overall market index S&P 500 is trading higher by 0.55% from its previous trading close, which means that Amgen stock is outperforming the overall market.

Amgen Inc (AMGN): Today's Featured Drugs Loser - TheStreet.com
From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - Benzinga
From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - Benzinga
From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - Benzinga
Amgen Stock To Go Ex-dividend Monday (AMGN) - TheStreet.com
Amgen Inc (AMGN): Today's Featured Drugs Winner - TheStreet.com
Amgen Reaches New 52-Week High (AMGN) - TheStreet.com
Benzinga's M&A Chatter for Wednesday April 25, 2012 - Benzinga
Amgen Goes to Turkey, Loses Biotech Cred - TheStreet.com
From Earlier: Amgen to Acquire Mustafa Nevzat; Company Valued at $700M - Benzinga

You could minimize risk by trading in stock sectors rather than individual stocks. Find out why ETFs are the hottest investment vehicle on the planet. Try ETF Profits for FREE NOW!